Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics gets approval for PQ Grass trial

Allergy Therapeutics has received approval for a phase II clinical trial of investigating the dosing of PQ Grass, an ultra-sho...

Approval for PQ Grass Phase II trial

RNS Number: 9660Q Allergy Therapeutics PLC 18 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Approval of clinical trial application for PQ Grass Phase II trial - Trial aimed at determining optimal dose of an MPL-adjuvanted, modified grass allergy vaccine - 18 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integra...

Allergy Therapeutics expands R&D and clinical team

Allergy Therapeutics has announced new senior appointments and expansion of the R&D and clinical team in line with th...

Expansion of Clinical Development and R&D teams

RNS Number: 2846Q Allergy Therapeutics PLC 11 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Expansion of Clinical Development and R&D teams - Key appointments reflect Group's commitment to EU and US strategy for product development - 11 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated special...

All News

DateHeadlineSource
24-03-14Allergy grows profits StockMarketWire
24-03-14Half Yearly ReportRNS
17-03-14Notice of ResultsRNS
12-03-14Shareholder updateRNS
19-02-14Health Canada approves Allergy CTA submission StockMarketWire
19-02-14Health Canada approves submission of CTARNS
11-02-14Holding(s) in CompanyRNS
27-01-14Allergy Therapeutics study results publishedStockMarketWire
27-01-14Results published in highly respected journalRNS
14-01-14Allergy Therapeutics revenues up 12%StockMarketWire
14-01-14Trading Update and Notice of ResultsRNS
20-11-13Allergy Therapeutics resolutions passed at AGMStockMarketWire
20-11-13Result of AGMRNS
20-11-13Allergy Therapeutics appoints R&D directorStockMarketWire
20-11-13Allergy Therapeutics revenues upStockMarketWire
20-11-13Business and R&D UpdateRNS
09-10-13Notification under AIM Rule Schedule Two (g)RNS
27-09-13Allergy Therapeutics appoints adviser StockMarketWire
27-09-13Change of AdviserRNS
19-09-13Holding(s) in CompanyRNS
16-09-13Allergy Therapeutics improves market shareStockMarketWire
16-09-13Final ResultsRNS
15-08-13Allergy Therapeutics schedules FY results StockMarketWire
15-08-13Notice of results and shareholder updateRNS
03-06-13Holding(s) in CompanyRNS
15-05-13Grant of OptionsRNS
08-05-13Holding(s) in CompanyRNS
08-05-13Holding(s) in CompanyRNS
25-03-13Half Yearly ReportRNS
11-03-13Allergy Therapeutics granted US patent StockMarketWire
11-03-13US patent grantedRNS
11-03-13Notice of results and shareholder updateRNS
01-02-13Total Voting RightsRNS
22-01-13Exercise of OptionsRNS
28-12-12Total Voting RightsRNS
27-12-12Update on Lincoln Medical FinalRNS
19-12-12Grant of OptionsRNS
10-12-12Director/PDMR ShareholdingRNS
05-12-12Total Voting RightsRNS
04-12-12Exercise of OptionsRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory